Abstract: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that results in diffuse muscle atrophy, which invariably involves the respiratory muscles. Most patients die of respiratory causes, including hypercapnic respiratory failure and pneumonia. Whether educating patients about pulmonary involvement, diagnosing respiratory muscle weakness, treating respiratory problems, or counseling patients about end-of-life decisions, pulmonologists can play an integral role in the care of patients with ALS. Serial evaluation of pulmonary function with spirometry is a basic element of ALS care. Complicated presentations may require more extensive evaluations, including supine spirometry, maximal inspiratory pressure, and arterial blood-gas analysis. Proper respiratory support of ALS patients can improve survival and quality of life. Available treatments include noninvasive positive pressure ventilation and mechanical insufflation-exsufflation. Tracheostomy ventilation should be included as a potential treatment option for ALS. While very few ALS patients opt for tracheostomy and long-term mechanical ventilation, for select patients, this can provide years of support with a preserved quality of life. Pulmonologists' experience with mechanical ventilation and critical care medicine provide unique expertise for discussing end-of-life issues such as hospice care, tracheostomy, and withdrawal of care. This review provides a general overview of ALS care and describes the pulmonary evaluation and treatment of patients with ALS.
A myotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which patients develop widespread muscle atrophy and spasticity. 1 While the disease usually falls under the purview of neurologists, patients with ALS almost universally develop respiratory muscle weakness and die of pulmonary complications. 2 Therefore, it is imperative that pulmonary physicians understand ALS. It was first described by Charcot in 1874 and is commonly known as Lou Gehrig disease in the United States, after the Yankee great who died of the crippling disorder in 1941. While it is an uncommon disorder, it is not rare. The worldwide incidence of ALS is estimated to be 0.6 to 2.6 cases per 100,000 people annually. The male to female ratio is 1.6:1, and the onset occurs most frequently in the sixth decade of life, though it can affect teens and octogenarians. 1 While a great deal of effort has been made to understand and cure ALS, the prognosis is still quite poor, with median survival from the time of diagnosis of roughly 3 years. Because of its rapid progression to death, ALS accounts for a disproportionately high number of deaths. It is estimated that ALS is responsible for 1 death for every 800 adult males in the United States.
ALS is characterized by both upper and lower motor neuron signs. Patients develop atrophy, fasciculations, and eventually flaccid paralysis of muscles from degeneration of motor neurons in the anterior horn of the spinal cord. Upper motor neuron signs such as hyperreflexia, clonus, and the Babinski reflex arise from degeneration of the corticospinal tracts. Virtually all skeletal muscles can be involved, but usually the bowel, bladder, and extraocular muscles are spared. Cranial nerve involvement is confined to the lower portions of the brainstem, or the "bulb." These are therefore called bulbar symptoms and consist of tongue and pharyngeal weakness. The corticobulbar tracts are also affected and contribute to bulbar symptoms, as well as emotional lability. Patients frequently progress to dysarthria, anarthria, dysphagia, and aphagia. Approximately 60% of patients present with limb involvement, and another quarter of patients initially present with bulbar symptoms. Fewer than 10% of patients have respiratory involvement as the initial symptomatic problem. 3 About 90% to 95% of ALS cases are sporadic and idiopathic, but there are also familial forms of the disease. The most common inherited form results from mutations in the superoxide dismutase (SOD) gene, which codes for a protein with antioxidant properties. 4 Epidemiologic studies have suggested several possible causes of ALS, including heavy-metal exposure, military occupation, and exposure to high-voltage power lines, but none of these have been confirmed. 5 There may also be an association between enterovirus infection and ALS. 6 Though there may be multiple inciting factors that result in ALS, a common pathophysiologic pathway may exist. This may include glutamate-mediated excitotoxicity, 7 oxidative stress, abnormalities of calcium regulation, and apoptosis.
ALS is a clinical diagnosis with no single conclusive diagnostic test. Other disorders that can mimic ALS include cervical spondylosis, spinal stenosis, myasthenia gravis, multifocal motor neuropathy, and hexosaminidase deficiency. 8 The workup generally includes electromyography, nerveconduction studies, and imaging of the brain and spine. 1 Frequently, lumbar puncture and blood tests are performed to exclude other etiologies. Criteria have been established to determine the certainty of the diagnosis based on electrodiagnostic testing and the clinical examination. 
Multidisciplinary Care of the ALS Patient
Comprehensive clinical management of the ALS patient includes evaluation by experienced ALS health care professionals. A comprehensive multidisciplinary health care team should include a neurologist, gastroenterologist, pulmonologist, advanced practice nurse, physical therapist, occupational therapist, respiratory therapist, nutritionist, speech therapist experienced in communication equipment, durablemedical-equipment supplier, and social worker. 10, 11 Each team member contributes unique knowledge and expertise to optimize the patient's quality of life.
Initially, the many psychosocial issues in ALS must be addressed, as the disease is one of continual change and loss. The succession of losses (loss of role, future plans, and independence) causes unpredictable periods of grief and mourning as the patient struggles to deal with each new phase of the disease. Each patient is unique in the techniques he uses to cope with the disease progression. In the end, most patients experience a fatalistic acceptance of the disease, but only after a long and often difficult struggle. Providing literature and referring patients to the Muscular Dystrophy Association and ALS Association web sites is helpful in mobilizing the patient to become an educated and integral member of his health care team. The maintenance of optimal function both physically and psychologically is very important.
Functional Disability/Adaptive Aids/Wheelchairs/Braces
Assessment of muscle strength, endurance, gait, and balance is important. Physical therapy and occupational therapy should be consulted as early in the diagnosis as possible and used throughout the disease course. Their role is to provide the patient with an individualized exercise and stretching program. Teaching patients safe and effective energy conservation and compensatory techniques is necessary to allow patients to carry out activities of daily living, including work and leisure activities. Providing safe and appropriate equipment to optimize functional abilities is crucial. It is necessary to discuss specific daily routines and hobbies and make suggestions about time management to maximize activity minimizing energy expenditure. 12, 13 Instruction to family members in lifting, transferring, bathing, toileting, and feeding is very important to the safety of the patient and can add significantly to their quality of life. Appropriate equipment and education in use of the equipment to all caregivers is vital to supporting the patient as the disease progresses. Patients with ALS have extensive need for supportive equipment, which can greatly improve functionality and quality of life ( Table 1) .
Treatment of Bulbar/Pseudobulbar Symptoms
Bulbar involvement causes many troublesome symptoms. These include hypersialorrhea (excessive salivation), dysarthria, and dysphagia. The former can be managed with pharmacologic agents and mechanical devices ( Table 1) .
Speech should be assessed at each clinic visit. The patient and family are generally the first to notice speech changes and problems. Assessment of speech includes the evaluation of volume, quality, and articulation, including which words are most misunderstood and time of the day speech is most affected. The health care professional should teach the patient relaxation and breathing techniques that maximize vocal volume. Proper positioning techniques should be discussed, such as directly facing the person being spoken to and sitting up straight with trunk muscles elongated to allow for maximum expansion of respiratory and chest muscles. The time when the patient's voice is strongest should be pinpointed so that patients can perform most business or telephone conversations at that time. Concise phrasing and exaggerated articulation are techniques often suggested by speech and language pathologists. Use of an answering machine and simple communication tools can minimize fatigue (Table 1) . Patients are advised to use both high-and low-technology communication systems, as computers are known to need repair on occasion.
ALS patients with dysphagia are at risk for insufficient nutrition and dehydration due to progression of muscle weakness, loss of coordination, and fatigue. Weakened muscles in upper extremities, as well as the muscles of the sophisticated swallowing function, affect an individual's ability to bring food to his or her mouth, chew sufficiently, and swallow the contents safely. The nutritional state is usually assessed by monitoring the patient's weight. Although weighing the patient can be difficult at times due to wheelchair confinement, the information is vital to assessment of a patient's nutritional state. Laboratory tests, tissue turgor, and mucus membrane moisture all assess a patient's hydration state. Referral to a speech language pathologist for a swallowing study should be done to evaluate risk of aspiration.
The patient and family members should be instructed on the signs of upper airway obstruction, the Heimlich maneuver, and the proper use of a portable suction machine with oral Yankauer adaptor. The patient should be encouraged to eat meals in a quiet, undistracted, and unhurried environment. Eating small frequent meals and the avoidance of difficult textures and consistencies (ie, salads, tough meat, waterconsistency liquids) should be encouraged. Adequate caloric intake should be discussed, with special attention to proper hydration and fiber intake as the patient's disease progresses. It is important to discuss creative ways to accomplish nutritional and hydration goals. Patients will progress to the point that adequate oral intake is impossible. Gastrostomy tubes have been shown to improve survival in ALS, 14 but the decision to pursue gastrostomy tube placement is difficult for most patients. The health care professional should begin the discussion as early as possible to give the patient enough time to make a thoughtful decision with the least amount of procedural risk. As the forced vital capacity (FVC) declines, the procedural risk rises and the choices for tube insertion methods may be limited. Educating the patient and family about the disease and prognosis is vitally important. Most important, the patient should talk to other ALS patients who have had a feeding tube placed, to patients who have refused a feeding tube, and to health care professionals who have assisted a patient through the procedure and provided the necessary follow-up care and troubleshooting of problems post-tube placement.
Pulmonary Evaluation (see Figure 1)
The pulmonary evaluation of patients with ALS should begin with a thorough history. Dyspnea and other respiratory complaints may be subtle or absent in patients with ALS in spite of respiratory muscle involvement. One study found ALS patients with a FVC as low as 38% predicted who did not have dyspnea. 15 Patients frequently have extensive limb weakness before the onset of respiratory muscle involvement. When this is the case, patients may be wheelchair bound and may not be able to exert themselves to the point of dyspnea. Medical providers must have a high index of suspicion and should inquire about orthopnea and sleep difficulties. Patients may report that their breathing feels more shallow than normal or that their voice is not as loud as it had been. Patients may notice that their cough is weaker than normal.
Respiratory muscle weakness can present initially with sleep symptoms. Lying supine places the diaphragm at a mechanical disadvantage. While asleep, there is a loss of any conscious control over respiration, and during rapid eye movement (REM) sleep there is paralysis of virtually all muscles except the diaphragm. Therefore, if a patient relies on the accessory muscles of respiration, they will have more problems with hypoventilation during REM sleep. A history of morning headaches is suggestive of nocturnal hypoventilation and hypercapnia but is rarely present and is usually a late finding. The physical examination can provide useful clues about respiratory status and can also provide prognostic information in patients with ALS. Patients with advanced diaphragmatic weakness will often appear uncomfortable and will have increased respiratory effort and rate. While percussion of the hemidiaphragms is frequently taught as the best physical examination test of diaphragm function, it can be difficult and is often unreliable. 16 Assessment of accessory muscles of respiration use and presence of abdominal paradox is easy to perform and is strongly associated with diaphragm weakness. 17, 18 Pulmonary function testing is the mainstay of the respiratory evaluation for patients with ALS. This can include spirometry, inspiratory and expiratory mouth pressures, transdiaphragmatic pressures, and sniff nasal pressures. The ALS Consensus Conference recommends measuring FVC at the time of diagnosis and then every 3 months. 8 FVC tends to decline linearly within patients, and an FVC below 50% is a predictor of 1-year mortality. Additionally, FVC is a better predictor of survival than ALS clinical scales. The average decline in FVC is approximately 3.5% predicted per month, but there is wide variation between patients. There are several important considerations with spirometry in patients with ALS. Patients with bulbar weakness or pseudobulbar symptoms may have difficulty performing spirometry due to air leaks around the mouth and incoordination. This can lead to falsely low values for FVC. Because of the sigmoid-shaped lung pressure/volume curve, lung volume and vital capacity can be maintained in spite of significant inspiratory muscle weakness. This can give clinicians a false sense of security, as patients may have a preserved FVC but may actually have severe diaphragmatic weakness. For this reason, one should consider additional measures of respiratory function.
FVC measured in the supine position is gaining popularity as an indicator of respiratory muscle weakness. When one moves from upright to supine, there is an increase in 
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Approach to the Patient With ALS strain on the diaphragm. This is due to increased pulmonary blood flow, altered position of the diaphragm, and the weight of the abdominal contents pressing against the diaphragm. In healthy subjects, the FVC falls by 7.5 Ϯ 5.7%. 19 The change from upright FVC to supine is increased in patients with diaphragm weakness. Supine FVC is a better predictor of diaphragm strength (transdiaphragmatic pressure, Pdi) and survival than upright FVC, 17, 18 and we recommend using supine FVC along with upright FVC for serial measurement of pulmonary function.
Maximal static inspiratory and expiratory mouth pressures (MIP and MEP) are sensitive measures of inspiratory and expiratory strength but are difficult to perform accurately, especially in patients with bulbar weakness. If MIP is normal (Ͼ Ϫ70 cm H 2 O), it is unlikely that the patient has significant inspiratory muscle weakness, but low values are difficult to interpret. Nevertheless, MIP is linearly associated with survival, and an abnormal MIP is associated with sleep-disordered breathing in patients with ALS. 20, 21 Furthermore, MEP is essentially the only readily available measure of expiratory strength. Inspiratory and expiratory muscles can be affected independently in ALS, and expiratory strength as measured by MEP is associated with survival. 18 Invasive measures of diaphragm strength, specifically Pdi and esophageal pressure, can be obtained reliably in patients with ALS and offer useful information. Pdi, the gold standard measure of diaphragm strength, is lower in symptomatic patients and has been shown to be the best predictor of respiratory failure. 22, 23 Because Pdi requires insertion of esophageal and gastric balloons, it is not practical for routine follow-up. It can be helpful in patients with unusual presentations who cannot perform spirometry well.
Sniff nasal pressure is a simple, noninvasive measurement that is gaining popularity. It is well correlated with esophageal pressure and can be performed more reliably than MIP in ALS patients. 24 It also appears to be more sensitive to respiratory muscle weakness and predicts respiratory failure better than FVC. 23 Though this is a relatively new test, it should become part of the standard battery for ALS patients.
The role of overnight oximetry and polysomnography in the evaluation and management of patients with ALS is not entirely clear, but there is growing evidence that these tests can provide clinically important information. Obstructive apneas occur more frequently in patients with bulbar involvement and more advanced respiratory involvement. 25, 26 It has been reported that between 17% and 76% of ALS patients have sleep-disordered breathing. 26 Nocturnal desaturation correlates with inspiratory muscle weakness 21 and can be used as a guide for initiating noninvasive positive-pressure ventilation (NIPPV). Patients with ALS can have relatively normal FVC but have nocturnal desaturation. 27 Furthermore, it has been shown in a recent study that patients who start using NIPPV based on nocturnal desaturation rather than daytime hypoxemia have improved survival. 28 These recent studies suggest that nocturnal oximetry and possibly polysomnography should be used more frequently in the evaluation of respiratory status in ALS.
While nocturnal gas-exchange abnormalities may be relatively common in ALS, daytime hypoxia and hypercapnia are uncommon and occur late in the course of the disease. 22, 29 Therefore, the authors do not recommend measuring arterial blood gas routinely in patients with ALS. Arterial blood gas analysis should be obtained only if patients have respiratory symptoms, disturbed sleep, morning headaches, or hypersomnolence.
Respiratory Treatments
Limitations in the understanding of ALS pathogenesis frustrate the discovery of therapies aimed against the disease process itself. In the absence of such advancements, treatment remains primarily symptomatic and supportive. Such treatment is of particular importance with regard to the pulmonary consequences of neuromuscular weakness, given that ALS mortality is primarily pulmonary in nature. 30 The ability to cough and clear respiratory secretions is hampered by inspiratory and expiratory muscle weakness, subjecting the patient to a significant risk of fatal aspiration. 31 Simultaneously, progressive respiratory weakness ultimately produces pulmonary restriction and progressive hypoventilation. 32 Treatments aimed at the pulmonary consequences of ALS thus tend to focus on ameliorating these 2 threats to host survival.
Prevention of Infection
In a defensive response to an infectious stimulus, the normal host increases production of both upper and lower respiratory secretions. 33, 34 In the ALS patient, this increased secretory burden can lead to asphyxiation, particularly given reported observations that upper respiratory infections can cause a transient worsening of already-compromised respiratory muscle strength. 31 Given this threat to the compromised host, providers should engage their ALS patients in aggressive primary prevention of infections. While no trial data yet exist to substantiate such practice, the theoretical gains are sufficient to support the routine vaccination of ALS patients against influenza and pneumococcus. 35 Such policies have already been adopted in the treatment of other neurologic disorders, such as muscular dystrophy or spinal muscular atrophy. 36 The secondary prevention of infection (eg, prophylaxis with antivirals such as oseltamivir) is of unknown utility but is a logical and reasonable approach when there is a high concern for influenza.
Reducing Airway Secretions
In an attempt to minimize the risk of aspiration in advanced ALS, several approaches to reducing upper and lower airway secretion production have been developed. Usual treatments of excessive upper airway secretion (ie, sialorrhea) include medication, suctioning, salivary gland surgery, radiation therapy, and even botulinum toxin injection. 37, 38 These have been discussed previously. The control of lower-airway secretions is derived from an understanding of airway epithelial physiology. As previously noted, infectious insults are potent stimulants of airway secretion production. Neurologic stimuli, however, also participate in this regulation. Increased ␤-adrenergic tone yields increased goblet-cell production of mucins. Cholinergic stimulation triggers the production of serous fluid that underlies the mucinous glycopeptide layer. 34, 39 Unfortunately, inhaled anticholinergic agents (eg, ipratroprium bromide) have had little effect on mucus secretion, 34 while systemic agents' (eg, atropine) efficacy is tempered by significant neurologic side effects. The use of ␤-antagonists has not been extensively studied, although one case series suggests some benefit for these agents.
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Improving Airway Clearance
The essential mechanism of airway protection is the ability to cough. Coughing requires a synchronization of 3 main actions: an inspiratory phase, in which lung insufflation occurs to 85% to 90% of total lung capacity; a compressive phase, in which expiratory muscles contract the inspired volume against a closed glottis; and a forceful expiration phase, in which the glottis is rapidly opened, with a resultant escape of the pressurized air (and up to a 300 mm Hg intrathoracic pressure change). 40, 41 This expulsion usually produces peak cough flow rates (measured via a peak flow meter during the act of coughing) of 6 L per second or greater. 41 In neuromuscular disease, the ability to cough is threatened by both bulbar dysfunction and respiratory muscle weakness. Without the ability to maintain a closed glottis, no amount of respiratory muscle tone or mechanical assistance will allow the production of intrathoracic pressures of sufficient magnitude to produce a viable cough. In this situation, tracheostomy is indicated to provide airway protection. 32, 42 Even if sufficient glottic tone exists, the ability to cough can be hampered by the presence of either inspiratory or expiratory muscle weakness. With inspiratory weakness, cough is limited by an inability to achieve insufflation of sufficient magnitude to produce adequate expiratory flow. With expiratory muscle weakness, adequate intrathoracic pressures cannot be obtained to produce acceptable peak cough flows. 32 Unlike bulbar dysfunction, inspiratory and expiratory muscle weakness can be treated with a variety of noninvasive modalities. Once a patient's peak cough flow drops below a certain threshold (eg, 270 to 300 L/min), authors have recommended patient training in assisted coughing. 32, 43 This assistance can be accomplished by an abdominal thrust during a cough (either by a caregiver or a specialized belt apparatus), mechanical insufflation/exsufflation (a device which stacks several positive-pressure facemask breaths before sudden changing to a negative pressure), or the combination of both. 32, 41 Use of mechanical insufflation/exsufflation has been shown to produce greater cough velocities than assisted-cough techniques alone. 44 Assuming stable glottic function, these processes may allow the creation and maintenance of peak cough flows greater than 160 L/min, a threshold deemed sufficient to allow airway clearance.
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Improving Ventilation
Even if an ALS patient is fortunate enough to avoid a fatal aspiration event, progressive ventilatory insufficiency remains inevitable. 45, 46 This progression can be forestalled with the initiation of positive-pressure ventilatory support. Noninvasive positive-pressure ventilation has been shown to reduce the rate of FVC decline, increase cognitive function, and improve overall patient survival in ALS. [47] [48] [49] [50] Fears of "prolonging death" by initiating NPPV have been allayed by studies demonstrating an improvement in the overall quality of life in ALS patients who use NPPV. 51, 52 Although protocols vary by center, bilevel ventilatory support is typically initiated with the development of respiratory symptomatology, a drop in FVC below 50% predicted, or an accelerated rate of FVC decline. 46, 49, 53, 54 Support is typically initiated at night (ie, in the supine position) with a nasal bilevel positive-airway-pressure device. Inspiratory and expiratory support is titrated to maintain a tidal volume of 12 to 15 mL/kg; 54 this goal becomes increasingly difficult to achieve with advancing weakness. 43 Ultimately, patients will require continuous ventilatory assistance. With aggressive secretion management, however, even this continuous support can be well tolerated. Once progressive bulbar weakness precludes the patient's ability to clear his or her secretions (even with mechanical assistance), noninvasive ventilation is no longer a viable treatment option. 34, 43, 54 The decision must then be made whether to proceed with tracheostomy or focus upon palliation.
Tracheostomy
Positive-pressure ventilation via tracheostomy has the theoretical capability of prolonging ALS survival indefinitely, albeit at increased costs to the patient and caregiver. [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] In reality, however, the consequences of recurrent aspiration superimposed upon ventilator-associated impairments in host defense usually lead to shortened survival. 56 Of those invasively ventilated patients with ALS who survive longer than 5 years, only 20% will become "locked in" (eg, the much-feared state of being cognitively intact yet unable to communicate). 56 Contrary to conventional wisdom, longterm survivors who remain communicative report a reasonably good quality of life, particularly if they were able to continue living at home. 55, 56 Regardless of these findings, 
Advanced Directives and End-of-Life Care
ALS has a highly predictable course, which makes it an ideal candidate disease for a disease-specific advanced directive. A disease-specific advanced directive has been published. 59 Advance directives should be discussed with the patient and his or her family as soon as a rapport is established. It is important that the family have a clear understanding of the patient's wishes regarding the gastrostomy tubes, tracheostomy and long-term ventilation, resuscitation, and life-support measures. Once the issues are discussed and understood by the patient and the family and a decision is made, written documents should be completed and shared with all health care professionals. 8, 53 Support of the patient and the family members by the health care professionals during the terminal stages is essential. No one should feel abandoned at this time. A timely response to phone calls, emergent clinic visits, and hospice requests may be necessary and are crucial for the patient to feel supported at this stage.
Palliative Care and Hospice
The total care of a patient with ALS needs to be carefully coordinated by a multidisciplinary health care hospice team as soon as the patient and family are identified as candidates for hospice programs. A hospice program, especially one with previous experience with an ALS patient, is uniquely skilled in dealing with the issues of the terminally ill and can ease some of the physical burden for the caregiver. Many hospices provide pastoral and bereavement counseling services. Many hospice programs are skilled and experienced in dealing with pain and symptom management during this stage of disease progression.
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Withdrawal of Life Support
Legal and ethical precedents support the right of mentally competent, informed patients to refuse or to discontinue any treatment, including life support and mechanical ventilation. Health care professionals are required to respect a request from a patient to refuse, remove, or discontinue use of any treatment such as feeding tube or mechanical ventilation.
Unfortunately, as ALS progresses, patients are ultimately rendered quadriplegic and are unable to speak except via an augmentative communication device. Circumstances of caregiver burden and financial situations often trigger a request for ventilation and life-support withdrawal. 62 A stepwise approach to ventilation withdrawal is suggested. Two separate careful discussions with the patient and family should be undertaken, approximately 6 to 8 weeks apart, to assess why ventilation withdrawal is being requested and whether interventions to resolve concerns can be initiated (ie, depression, care-giving burden issues, or financial issues).
When approaching ventilation withdrawal, the primary goal is to maintain patient comfort. Family members may wish to be present. Cultural and religious rituals should be discussed, planned, and implemented as requested by the patient and their family. Pretreatment with medication prior to each step should be used. Sedative-hypnotic and opioid medications should be titrated to relieve anxiety and dyspnea, even to the point of unconsciousness if necessary and/or if requested by the patient. 35 Termination of supplemental oxygen, end positive expiratory pressure, followed by conversion to spontaneous breathing is recommended. The use of a muscleparalyzing agent during ventilation withdrawal is not appropriate or supported in the literature.
Future Directions and Conclusions
ALS is among the neurologic diseases in which the most therapeutic trials have been conducted. 63 It is also an area of intense scientific investigation in the basic science laboratory. Despite these efforts, ALS remains idiopathic, and there is only 1 FDA-approved drug for the treatment of ALS. Riluzole was approved by the FDA on the basis of 2 clinical trials that showed a small (3-to 6-month) survival benefit for subjects treated with riluzole 64, 65 and is now considered standard therapy for all patients with ALS. However, numerous breakthroughs in the understanding and treatment of ALS have occurred in recent years.
One of the greatest tools in the understanding and treatment of ALS has come from the development of transgenic mouse and rat models of ALS. These animals express the mutant SOD1 protein and develop clinical disease that is similar to human ALS. This has furthered the understanding of the important role oxidative injury plays in ALS and possibly more importantly has led to the rapid development of new therapeutic strategies. Two new approaches to treating ALS that have generated enthusiasm are stem cell therapy and gene therapy. Kerr and colleagues 66 recently demonstrated that rats with a viral-induced motor neuropathy regained limb function after receiving transplantation of human embryonic germ cells. Kaspar and colleagues 67 recently demonstrated that insulin growth factor 1 could be transported via adeno-associated virus to limb and respiratory motor neurons of SOD1 mutant mice and that these animals had delayed disease progression and prolonged survival. While many proposed therapies have looked promising in animals but failed to work in human trials, these are novel approaches to treating ALS that will hopefully move to human trials in the coming years.
ALS is a devastating disease, but there is a flurry of research ongoing that is yielding encouraging results for the near future. In the meantime, supportive respiratory care is imperative and can improve not only the duration but also the quality of survival in ALS. Multidisciplinary groups that include pulmonary expertise should provide care for patients with ALS. Ongoing respiratory evaluation is critical to educate patients, prevent respiratory complications, and make decisions about ventilatory support.
